• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

News and Updates for Bladder Cancer Awareness Month


A roundup of some of CURE®’s latest news and updates for patients with bladder cancer in honor of Bladder Cancer Awareness Month this May.

To honor Bladder Cancer Awareness Month this May, CURE® is taking a look at some of the most recent updates in the disease space.

  • In a recent episode of the “CURE® Talks Cancer” podcast, we spoke with a cancer research writer, Henry Scowcroft, about his experiences writing a book about his late wife’s cancer journey and offers advice for other caregivers.
  • In April, the Food and Drug Administration (FDA) granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for patients with locally advanced or metastatic urothelial cancer, who have previously received platinum chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
  • Overall survival and progression-free survival did not significantly differ when adjusting the dose of cisplatin in combination with Abraxane (paclitaxel protein-bound) and gemcitabine in patients with advanced/metastatic urothelial carcinoma, according to a study published in Urologic Oncology.
  • In early March, Tecentriq’s (atezolizumab) indication for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or after platinum-based chemotherapy was pulled by the FDA and the drug’s manufacturer, Roche.
  • While it is important to educate oneself after receiving a diagnosis of cancer, it’s also critical to know when to step away and find a balance between cancer and life, according to Diane Zipursky-Quale, co-founder of the Bladder Cancer Advocacy Network (BCAN).

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Psutka in an interview with CURE
Dr. Sarah Psutka in an interview with CURE at the ASCO Annual Meeting
Kristie L. Kahl and Dr. Tracy L. Rose
Dr. Tracy Rose
Dr. Tracy L. Rose
Kristie L. Kahl and Tracy L. Rose
Kristie L. Kahl
Related Content